It’s Christmas in July for at least one small biotech and, possibly, some major pharmaceutical companies. They had assumed a class of drugs they’re developing might work in a rare, genetic form of Parkinson’s disease that accounts for 3 or 4 percent of cases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,